GSK’s Anoro Ellipta beats BI’s Spiolto Respimat in COPD trial

2nd November 2017 Uncategorised 0

GlaxoSmithKline and Innoviva say their combination lung therapy Anoro Ellipta has come out on top in a trial pitting its effectiveness in improving lung function against that of Boehringer Ingelheim’s Spiolto Respimat.

More: GSK’s Anoro Ellipta beats BI’s Spiolto Respimat in COPD trial
Source: News